The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Kapeleris, Joanna; Kulasinghe, Arutha; Warkiani, Majid Ebrahimi; Vela, Ian; Kenny, Liz; O’Byrne, Kenneth J.; Punyadeera, Chamindie

doi:10.3389/fonc.2018.00311

Cited by 97 publications

(99 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous research has shown that CTCs can also cause tumor recurrence and are related to patient prognosis . The ability to obtain more information from CTCs may therefore offer an avenue toward the early detection of cancer, allowing researchers to gain insight into its the aggressive nature of the tumor and offering a means of monitoring therapeutic responses and disease progression in patients …”

Section: Introductionmentioning

confidence: 99%

“…6,7 The ability to obtain more information from CTCs may therefore offer an avenue toward the early detection of cancer, allowing researchers to gain insight into its the aggressive nature of the tumor and offering a means of monitoring therapeutic responses and disease progression in patients. [8][9][10] In 2004, the CellSearch system was approved by FDA as a means of detecting CTCs in breast cancer, prostate cancer, and colorectal cancer patients given their promise as biomarkers useful for monitoring chemotherapeutic efficacy. [11][12][13] These CellSearch systems relied upon detecting CTCs based on their surface expression of epithelial cell adhesion molecules (EpCAM) and cytokeratins (CK).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

et al. 2019

View full text Add to dashboard Cite

Background Lung cancer has the highest fatality rate of all cancer types. To improve patients’ survival and life quality, it is therefore very important to screen for and detect it at an early stage. Methods A negative enrichment–fluorescence in situ hybridization (NE‐FISH) approach was used to detect circulating tumor cells (CTCs) in lung cancer patients, and levels of lung cancer‐associated serum markers were also measured in the peripheral blood of these same patients. The correlation between CTCs, serum cancer markers (carcinoembryonic antigen [CEA], CA 125, CYFRA 21‐1, and SCC), and clinicopathological characteristics was then investigated. Moreover, the potential clinical use of the combination of CTCs and tumor markers for the diagnosis of lung cancer, especially at early stages, was also explored. Results CTC frequencies in lung cancer patients were significantly higher than in healthy control volunteers or patients with benign lung disease, and the area under the receiver operating characteristics curve for the control group was 0.846 (95% CI 0.796‐0.887, P < 0.001). The rate of CTC positivity in lung cancer patients was 68.29% when the CTC cutoff value was 2, and the sensitivity of this means of lung cancer detection rose to 82.93% by combining CTC‐based detection with measurements of serum tumor markers. Similarly, the diagnostic sensitivity of this approach in early‐stage lung cancer patients (I‐II) was improved from 63.93% to 78.69%. Detection of CTCs can thus assist with the identification of benign and malignant pulmonary nodules. Conclusions It is potentially helpful and effective to employ a combination of CTCs and serum tumor markers for the clinical diagnosis of lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…CTCs have shown strong potential in the diagnosis of lung cancer, 42 and currently are being actively considered for their prognostic capacity as well. 43 Overall, clinical evidence supports the potential of the CTC count as a predictor of survival in both patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 12 For patients with SCLC, which is a particularly aggressive lung cancer affecting approximately 15% of patients, CTCs are capable of distinguishing between Circulating Tumor Cells as Biomarkers/Jin et al chemorefractory and chemosensitive SCLC.…”

Section: Ctcs and Lung Cancermentioning

confidence: 95%

“…CTCs have shown strong potential in the diagnosis of lung cancer, and currently are being actively considered for their prognostic capacity as well . Overall, clinical evidence supports the potential of the CTC count as a predictor of survival in both patients with small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC) .…”

Section: Introductionmentioning

confidence: 96%

“…For patients with SCLC, which is a particularly aggressive lung cancer affecting approximately 15% of patients, CTCs are capable of distinguishing between chemorefractory and chemosensitive SCLC . Several recent studies have found that CTCs also can be useful for NSCLC, which accounts for approximately 80% of lung cancers . CTCs can be especially useful when the expression of specific markers within the cells is considered.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

Smart Material‐Integrated Systems for Isolation and Profiling of Rare Cancer Cells and Emboli

Sagdic

İnci

2021

Adv Eng Mater

View full text Add to dashboard Cite

This review presents a broad aspect of smart material‐integrated systems for isolating and profiling rare circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) to provide physiological, biological, and mechanistic insights into cancer research. In particular, CTCs/CTM have emanated as essential pieces of evidence that can reveal clonal evolution, tumor heterogeneity, and disease progression within the metastatic cascade. Morphologies, cellular compositions, and rarity of CTCs/CTM make them difficult to track and isolate for profiling distinct molecular characteristics in the case of metastatic potential. Accordingly, with the advanced‐characterization techniques, examining the aspects of the specific surface markers of CTCs/CTM, epithelial‐to‐mesenchymal (EMT), mesenchymal‐to‐epithelial (MET) transitions, and timing of tumor cell dissemination would assist us to understand cancer biology and metastatic characteristics. Existing clinical and research methods for the enrichment and isolation of these sporadic cells depend on mainly conventional methods with low‐yield and expensive features. Owing to their specialized functions and analytical performances, smart material‐based technologies hold an enormous impact not only on cell detection, but also on cell isolation for downstream analyses. Herein, the main reasons for cell isolation are discussed and the recent developments in CTCs/CTM approaches for identifying further methods and future perspectives are elaborated on.

show abstract

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer

Cited by 97 publications

References 159 publications

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Smart Material‐Integrated Systems for Isolation and Profiling of Rare Cancer Cells and Emboli

Contact Info

Product

Resources

About